US Patent

US10617695 — Ophthalmic compositions containing alcaftadine

Method of Use · Assigned to Vistakon Pharmaceuticals LLC · Expires 2027-03-19 · 1y remaining

Vulnerability score 80/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects ophthalmic compositions containing alcaftadine or a pharmaceutically acceptable salt thereof for treating or preventing ocular allergies and inflammation.

USPTO Abstract

Compositions, kits and methods for the treatment or prevention of ocular allergies and inflammation and the symptoms thereof containing alcaftadine or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Lastacaft (ALCAFTADINE) · AbbVie

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3267`	—	Lastacaft

Patent Metadata

Patent number: US10617695
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-19
Drug substance claim: No
Drug product claim: Yes
Assignee: Vistakon Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.